



#16A/184

Docket No. 58729 (48933)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: WOLOZIN, Benjamin *et al.*  
Serial No.: 09/901,187  
Filing Date: July 9, 2001  
Title: METHODS FOR PREVENTING NEURAL TISSUE DAMAGE AND FOR THE TREATMENT OF ALPHA-SYNUCLEIN DISEASES

Examiner: O. Chernyshev  
Group No.: 1646

Commissioner for Patents  
Washington, D.C. 20231

Sir:

AMENDMENT IN RESPONSE TO NOTICE UNDER 37 CFR §1.821-825

In response to the Notice to Comply With Requirements for Applications Containing Sequence Disclosures mailed February 27, 2003, please amend the application as follows:

**In the Specification:**

Please amend the specification as shown:

Please delete the paragraph on page 12, lines 22-30, thru page 13, lines 1-9 and replace it with the following paragraph:

A

Such peptides can be found, for instance, by using phage display to select for those phage expressing a peptide on their surface that binds to  $\alpha$ -synuclein, and determining what the peptide is. The inhibitory effect of that peptide, or any peptide for that matter, can also be tested to determine its usefulness as an agent for treating a Lewy body disease or synucleinopathy by using assays such as those disclosed herein or as disclosed in US Patent No. 6,184,351, which is incorporated herein by reference. Such peptides have been selected for their ability to bind to the C-terminal (approx. amino acids 113- 140), and the NAC portion (approx. amino acids 61 - 87) of  $\alpha$ -synuclein, because this region is thought to be involved with the aggregation process. Several peptides that bind to the C-terminal portion are as follows (all peptides are given in

RECEIVED  
MAY 06 2003  
TECH CENTER 1800/2800